J A Light1, D Y Barhyte. 1. Washington Hospital Center, Washington DC 20010, USA.
Abstract
INTRODUCTION: Herein we report 10- to 15-year results of simultaneous pancreas-kidney (SPK) transplants in 135 type I and type II insulin-dependent diabetes mellitus (IDDM) patients. METHODS: Diabetes type was defined by the absence (type I) or presence (type II) of C-peptide. The freedom from dialysis and need for insulin defined graft survival. Patient survival was verified by record review and the Social Security Death Registry. The mean follow-up exceeded 100 months. RESULTS: Type II IDDM present in 28% of the 135 cohort, predominately among African-Americans (AA). The type II group was two-thirds AA (43% of the total AA patients) and 17% of the non-African-American (nAA) group. The difference between the two groups by C-peptide level was significant (P = .001). Type II patients had a higher body mass index, were slightly older at the onset of DM, but had similar duration of IDDM before ESRD. At 5 and 10 years, pancreas survival for type 1 DM was 71% and 49%; for type II DM it was 67% and 56% (P = .52). Kidney survival for type I DM was 77% and 50%; for type II it was 72% and 56% (P = .65). Patient survival for type I DM was 85% and 63%; for type II DM it was 73% and 70% (P = .98). CONCLUSIONS: We conclude that the outcomes of SPK transplants are equivalent regardless of diabetes type. Accordingly, the decision whether to perform pancreas transplants in diabetic recipients of kidney allografts should be based on general acceptance criteria not diabetes type.
INTRODUCTION: Herein we report 10- to 15-year results of simultaneous pancreas-kidney (SPK) transplants in 135 type I and type II insulin-dependent diabetes mellitus (IDDM) patients. METHODS:Diabetes type was defined by the absence (type I) or presence (type II) of C-peptide. The freedom from dialysis and need for insulin defined graft survival. Patient survival was verified by record review and the Social Security Death Registry. The mean follow-up exceeded 100 months. RESULTS:Type II IDDM present in 28% of the 135 cohort, predominately among African-Americans (AA). The type II group was two-thirds AA (43% of the total AA patients) and 17% of the non-African-American (nAA) group. The difference between the two groups by C-peptide level was significant (P = .001). Type IIpatients had a higher body mass index, were slightly older at the onset of DM, but had similar duration of IDDM before ESRD. At 5 and 10 years, pancreas survival for type 1 DM was 71% and 49%; for type IIDM it was 67% and 56% (P = .52). Kidney survival for type I DM was 77% and 50%; for type II it was 72% and 56% (P = .65). Patient survival for type I DM was 85% and 63%; for type IIDM it was 73% and 70% (P = .98). CONCLUSIONS: We conclude that the outcomes of SPK transplants are equivalent regardless of diabetes type. Accordingly, the decision whether to perform pancreas transplants in diabetic recipients of kidney allografts should be based on general acceptance criteria not diabetes type.
Authors: Jeffrey Rogers; Alan C Farney; Samer Al-Geizawi; Samy S Iskandar; William Doares; Michael D Gautreaux; Lois Hart; Scott Kaczmorski; Amber Reeves-Daniel; Stephanie Winfrey; Mythili Ghanta; Patricia L Adams; Robert J Stratta Journal: Rev Diabet Stud Date: 2011-05-10
Authors: H A Chakkera; J K Bodner; R L Heilman; D C Mulligan; A A Moss; K L Mekeel; M J Mazur; K Hamawi; R M Ray; G L Beck; K S Reddy Journal: Transplant Proc Date: 2010-09 Impact factor: 1.066
Authors: Edmund Q Sanchez; Larry B Melton; Srinath Chinnakotla; Marlon F Levy; Bernard V Fischbach; Robert Goldstein; Göran B Klintmalm Journal: Proc (Bayl Univ Med Cent) Date: 2010-01
Authors: J K Melancon; L M Kucirka; L E Boulware; N R Powe; J E Locke; R A Montgomery; D L Segev Journal: Am J Transplant Date: 2009-10-21 Impact factor: 8.086
Authors: Erika B Rangel; João R de Sá; Cláudio S Melaragno; Adriano M Gonzalez; Marcelo M Linhares; Alcides Salzedas; José O Medina-Pestana Journal: Diabetol Metab Syndr Date: 2009-08-26 Impact factor: 3.320